Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Breast Neoplasms 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Melanoma 5Glioblastoma 5Carcinoma, Transitional Cell 5Ovarian Neoplasms 4Advanced Solid Tumor 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Liver Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Solid Cancer 2Small Cell Lung Cancer Extensive Stage 2Recurrence 2Neuroendocrine Tumors 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

pembrolizumab 1liposomal doxorubicin 1fludarabine phosphate 1atezolizumab 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenoviridae Infections × atezolizumab × Clear all
NCT02705196 2026-02-24

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Lokon Pharma AB

Phase 1/2 Completed
51 enrolled
Gastrointestinal

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡